Comparison of reproductive performance of primiparous dairy cattle following revaccination with either modified-live or killed multivalent viral vaccines in early lactation.

The objective of this randomized clinical trial was to compare the effect of revaccination in primiparous dairy cows with modified live viral (MLV) or killed viral (KV) vaccines containing bovine viral diarrhea virus (BVDV) and bovine herpesvirus-1 (BoHV-1) on (1) pregnancy rate following estrus synchronization-timed artificial insemination (TAI), (2) serum progesterone concentrations, and (3) serum neutralizing antibody titers at revaccination and at TAI. Primiparous dairy cows (n=692) that had been previously vaccinated with 4 doses of MLV vaccine as calves or heifers were randomized to receive either an MLV or a KV vaccine between 21 and 28 d in milk and 17 d before initiation of a double-Ovsynch-TAI protocol. Serum was collected within the double-Ovsynch protocol for determination of progesterone concentrations, and at vaccination and TAI for serum neutralizing antibody titers. Ultrasound pregnancy determinations were made at 30 and 60 d after TAI. No differences in pregnancy rates were observed between cows receiving MLV vaccine (44%; n=326) or KV vaccine (43%; n=336). No differences were observed in serum progesterone concentrations during a double-Ovsynch-TAI protocol between cows receiving MLV and KV vaccines. No differences were observed in BVDV 1 or BVDV 2 antibody titers at vaccination and TAI between cows receiving MLV or KV vaccine; however, BoHV-1 antibody titers were greater at TAI in cows receiving KV vaccine. Overall response to vaccination-defined as the percent of all individual cows that had any detectable increase in antibody titer from vaccination to TAI-was 39% for BVDV 1, 45% for BVDV 2, and 61% for BoHV-1. In this research, use of an MLV vaccine did not impede reproduction when revaccination was performed between 21 and 28 DIM and just before enrollment in an estrus synchronization-TAI program in primiparous dairy cows; however, response to vaccination as defined by increases in virus-specific antibody titers could be considered less than ideal for this population of cattle.

Exposure of neonatal rats to anti-androgens induces penile mal-developments and infertility comparable to those induced by oestrogens.

We previously reported that oestrogen exposure in neonatal rats induced permanent infertility and malformed penis characterized by fat accumulation, which replaced most of the smooth muscle cells and cavernous spaces in the body of the penis, structures essential for erection. The objective of this study was to determine if reduced androgen production/action in the neonatal period, in the absence of exogenous oestrogen exposure, induces penile deformities similar to those caused by oestrogen. Male rats were treated from postnatal days 1-6 with GnRH antagonist antide (A, 10 mg/kg) or androgen receptor (AR) antagonist flutamide (F, 50 mg/kg) or F + A, with or without AR agonist dihydrotestosterone (DHT, 20 mg/kg). For comparison, pups received diethylstilbestrol (DES, 0.1 mg/kg), with or without DHT. Tissues were collected at ages 7 and 12 days and at adulthood. Flutamide alone decreased penile length and weight significantly (p < 0.05), but it caused neither fat accumulation, nor affected fertility (80% vs. 87% in controls). Antide alone reduced penile length and weight significantly, and induced fat accumulation in 4/11 rats and infertility in 13/14 rats. Conversely, all 11 F + A-treated rats, similar to all nine DES-treated rats, had fat accumulation and loss of smooth muscle cells and cavernous spaces in the body of the penis and were infertile. In addition, reductions in penile length and weight were higher than in rats treated with F or A alone. DHT co-administration mitigated penile deformities in the DES group, but did not in the F + A group. Testicular testosterone was reduced by 70-95% at 7 or 12 days of age in all treated groups, except in the F group, which had threefold higher testosterone than controls. Collectively, data unequivocally show that reduced androgen production/action in the neonatal period, in the absence of oestrogen exposure, induces permanent infertility and malformed penis similar to that caused by oestrogen.

Estrogen-induced developmental disorders of the rat penis involve both estrogen receptor (ESR)- and androgen receptor (AR)-mediated pathways.

This study tested the hypothesis that the estrogen receptor (ESR) pathway, androgen receptor (AR) pathway, or both mediate estrogen-induced developmental penile disorders. Rat pups received diethylstilbestrol (DES), with or without the ESR antagonist ICI 182,780 (ICI) or the AR agonist dihydrotestosterone (DHT) or testosterone (T), from Postnatal Days 1 to 6. Testicular T concentration, penile morphology and morphometry, and/or fertility was determined at age 7, 28, or 150 days. DES treatment alone caused 90% reduction in the neonatal intratesticular T surge; this reduction was prevented by ICI coadministration, but not by DHT or T coadministration. Unlike the T surge, coadministration of ICI and coadministration of DHT or T mitigated penile deformities and loss of fertility. Generally, ICI, DHT, or T treatment alone did not alter penile morphology; however, fertility was 20% that of controls in ICI-treated rats vs. 70%-90% in DHT- or T-treated rats. The lower fertility in the rats treated with ICI alone could be due to altered sexual behavior, as these males did not deposit vaginal plugs. In conclusion, observations that both an ESR antagonist and AR agonists prevent penile deformities and infertility suggest that both pathways are involved in estrogen-induced penile disorders. Observations that coadministration of ICI, but not DHT or T, prevents the DES-induced reduction in the neonatal T surge suggest that, although ICI exerts its mitigating effect both at the level of Leydig cells and penile stromal cells, DHT and T do so only at the level of stromal cells.

Estrogen-induced abnormal accumulation of fat cells in the rat penis and associated loss of fertility depends upon estrogen exposure during critical period of penile development.

We previously reported that diethylstilbestrol (DES) or estradiol valerate (EV) exposure at a dose of 0.10-0.12 mg/kg, or higher, per day, on alternate days, from postnatal days 2-12, resulted in abnormal penis development and infertility (H. O. Goyal et al., 2005, J. Androl. 26, 32-43). The objective of this study was to identify a critical developmental period(s) during which EV exposure results in the observed penile abnormalities. Male pups received EV at a dose of 0.10-0.12 mg/kg on postnatal day(s) 1, 1-3, 4-6, 1-6, 7-12, 13-18, 19-24, or 25-30. Fertility was tested at 102-115 days of age and tissues were examined at 117-137 days. Both penile morphology and fertility were unaltered in rats treated with EV after 12 days of age. Conversely, except in rats treated on postnatal day 1 only, none of the males treated prior to 12 days of age sired pups, and all had abnormal penises, including varying degrees of abnormal accumulation of fat cells and loss of cavernous spaces and smooth muscle cells in the corpora cavernosa penis, which were maximal in the 1-6-day group. Also, the preputial sheath was partially released or its release was delayed, and the weight of the bulbospongiosus muscle was significantly reduced. Plasma testosterone (T) in the 1-6- and 4-6-day groups and intratesticular T in the 4-6-day group were significantly lower. The testosterone surge, characteristic of controls in the first week of life, was suppressed in the 1-3-day group. Estrogen receptor alpha mRNA expression was enhanced in the body of the penis in the 1-3-day group, but not in the 13-18-day group. Hence, EV exposure prior to 12 days of age (as short as 1-3 days postnatal), but not after 12 days of age, results in long-term abnormal penile morphology, characterized by abnormal accumulation of fat cells in the corpora cavernosa penis and, consequently, loss of fertility.

Activin-A stimulates the synthesis of gonadotropin-releasing hormone receptors.

The number of GnRH receptors on gonadotropes is regulated by GnRH as well as by heterologous modulators. We have used the density shift technique to measure the synthetic rate of GnRH receptors in pituitary cell cultures and found it to be stimulated by GnRH, an action that is antagonized by inhibin. In the present study, we evaluated the effects of activin-A on the GnRH receptor synthesis rate as well as effects of activin on stimulation of GnRH receptor synthesis by the homologous hormone. Recombinant human activin-A (50 ng/ml) was incubated with pituitary cell cultures from female weanling rats and the incorporation of densely labeled amino acids into receptors for GnRH was measured. The rate of GnRH receptor synthesis of cells treated with activin (50 ng/ml) together with either GnRH (0.1 ng/ml) or inhibin (12 ng/ml) was also quantified. Activin significantly stimulated the synthetic rate of GnRH receptors similarly to that observed after GnRH treatment (time for synthesis of half the population of GnRH receptors was 12.6 +/- 1.1, 16.1 +/- 1.3 vs. 28.3 +/- 1.2 h for GnRH, activin, and control, respectively), although the time course for stimulation by GnRH and activin appeared to differ. Inclusion of activin in cultures did not affect homologous stimulation of GnRH receptor synthesis. The stimulatory effects of activin were unaffected by combined treatment with inhibin (t1/2 of synthesis 17.2 +/- 2.0 h). Together, these data indicate that activin stimulates GnRH receptor synthesis in cell culture through a distinct mechanism from GnRH. Additionally, inhibin did not antagonize the stimulatory effects of activin on synthesis of GnRH receptors. This is, to our knowledge, the first demonstration of an action of activin-A on GnRH receptor synthesis.

Altered rate of synthesis of gonadotropin-releasing hormone receptors: effects of homologous hormone appear independent of extracellular calcium.

Steady state levels of plasma membrane receptors (measured in radioligand assays) result from processes that contribute to the production of receptors (synthesis, recycling, and unmasking) as well as those that contribute to the loss of receptors (degradation, internalization, and inactivation). Accordingly, we have previously adapted the density shift technique to determine the contribution due to synthesis of GnRH receptors. In the present study we have evaluated the ability of homologous hormone to affect the rate of synthesis of these receptors. Additionally, because of its role in other actions of the releasing hormone, the requirement for extracellular Ca2+ to mediate the effects of GnRH was assessed. Cultures of pituitary cells, prepared from female weanling rats, were used for all studies. After treatment with GnRH, a GnRH antagonist, or the calcium ionophore A23187, with or without EGTA (a calcium chelator), cells were further cultured for up to 24 h in medium containing either dense or normal amino acids. After this treatment, receptors for GnRH were covalently linked to a radiolabeled photoaffinity probe [( 125I]Tyr5-[azido-benzoyl-D-Lys6-GnRH]) then solubilized in 1% sodium dodecyl sulfate. Receptors that had incorporated the dense amino acids (i.e. newly synthesized receptors) were separated from those that had been synthesized before the addition of dense amino acids by velocity sedimentation in sucrose gradients (0-20% sucrose, 1% sodium dodecyl sulfate, and 10 mM Tris-HCl, pH 7.0; centrifuged at 156,000 x g for 24 h). After centrifugation, gradients were fractionated, and the radioactivity in each fraction was quantified. GnRH treatment (10 or 0.1 nM) increased the rate at which dense amino acids were incorporated into GnRH receptors (t 1/2 = 13 +/- 2, 15 +/- 1, and 25 +/- 2 h for 0.1 nM GnRH, 10 nM GnRH, and control values, respectively). GnRH antagonist alone did not change the rate of GnRH receptor synthesis (t 1/2 = 22 +/- 3 h) compared to the control value (t 1/2 = 25 +/- 2 h) and was able to block the effects of GnRH. The effects of GnRH were not antagonized by inclusion of 3 mM EGTA during treatment (t 1/2 = 15 +/- 1 h vs. 13 +/- 2 h for 0.1 nM GnRH in the presence and absence of 3 mM EGTA, respectively).(ABSTRACT TRUNCATED AT 400 WORDS)

Protein kinase-C activation stimulates synthesis of gonadotropin-releasing hormone (GnRH) receptors, but does not mediate GnRH-stimulated receptor synthesis.

Gonadotropes respond to GnRH with LH synthesis and release, desensitization, changes in GnRH receptor number, and GnRH receptor synthesis. Activation of protein kinase-C (PKC) appears to be involved in LH beta gene expression, but is not required for acute LH release, desensitization, or receptor down-regulation. The present studies were conducted to determine whether PKC mediates GnRH-stimulated receptor synthesis. We have adapted the density shift technique to measure the synthesis of GnRH receptors in pituitary culture. Pituitary cells from female weanling rats were exposed to medium containing treatments, dense amino acids (greater than 95% 13C, 15N, and 2H), dialyzed horse serum (10%, vol/vol), and fetal calf serum (2.5%, vol/vol). Treatments consisted of medium alone, phorbol myristate acetate (PMA), phorbol dibutyrate (PdBu), or GnRH. To deplete cells of PKC, cultures were exposed for 8-16 h to 1 microM PMA. Short term treatment with PKC activators (PMA or PdBu, 1 microM) or GnRH (0.1 nM) was given for 30 min. After treatment, GnRH receptors were covalently linked to [125I]Tyr5-azidobenzoyl-D-Lys6-GnRH and solubilized. Newly synthesized (densely labeled) GnRH receptors were separated from normal receptors by velocity sedimentation (156,000 X g; 24 h; 0-20% sucrose) and quantified by gamma-spectroscopy. Treatment with GnRH significantly stimulated the synthesis of GnRH receptors. Treatment of pituitary cell cultures with PMA (8-16 h) also stimulated the synthesis of GnRH receptors, although to a lesser extent than that observed after GnRH treatment. The synthesis of GnRH receptors in response to 0.1 nM GnRH was not different in cells with a normal complement of PKC compared to those depleted of PKC activity. This indicates that the ability of GnRH to stimulate the synthesis of its own receptor is not mediated by PKC. Short term treatment of cell cultures with 1 microM PMA or PdBu (30 min) stimulated GnRH receptor synthesis similar to treatment with 0.1 nM GnRH. When PMA and GnRH were administered simultaneously, GnRH receptor synthesis was stimulated to a greater extent than with either agent alone, suggesting differing mechanisms of action. These results indicate that although activators of PKC can stimulate the synthesis of GnRH receptors, PKC does not mediate the effects of GnRH on homologous receptor synthesis.

Synthesis of gonadotropin-releasing hormone receptors by gonadotrope cell cultures: both preexisting receptors and those unmasked by protein kinase-C activators show a similar synthetic rate.

Responsiveness of gonadotropes to GnRH depends, in part, on the number of plasma membrane GnRH receptors. Since the steady state level of these plasma membrane receptors is a function of the rates of both receptor generation (synthesis, unmasking, and recycling) and loss (internalization, degradation, and inactivation) we have sought to quantify the rate of synthesis of GnRH receptors in pituitary cell cultures. Further, since the protein kinase-C activator phorbol 12-myristate 13-acetate (PMA) has been shown to unmask a class of GnRH receptors that appear to be uncoupled from phosphoinositide turnover, we have measured the rate of synthesis of this second receptor population. The present studies use the density shift technique; incorporation of densely labeled amino acids confers a higher density to newly synthesized proteins and allows their separation by physical means. Cultures of pituitary cells were prepared from female weanling rats. After cells had attached to the culture dishes, medium was replaced at 12-h intervals with medium containing either densely labeled or normal amino acids. After the incubation, GnRH receptors were covalently linked to a photoaffinity receptor agonist [( 125I]Tyr5-[azido-benzoyl-D-Lys6-GnRH]), then solubilized with 1+ sodium dodecyl sulfate. In some cultures PMA (50 nM) was included during the photoaffinity agonist-binding step. Newly synthesized (dense) receptors were separated from previously synthesized receptors by velocity sedimentation (0-20% sucrose in 1% sodium dodecyl sulfate-10 mM Tris-HCl, pH 7.0; centrifuged at 156,000 x g for 24 h). Gradients were fractionated, and the radioactivity contained in each fraction was quantified. Newly synthesized GnRH receptors exhibited a higher density, as evidenced by further migration into the gradient, than did normal GnRH receptors. There was a delay of approximately 6 h between exposure to dense amino acids and the appearance of densely labeled GnRH receptors at the plasma membrane. Equilibrium for incorporation of dense amino acids into GnRH receptors was 48 h of exposure to dense amino acids. The time required for synthesis of half the entire population of GnRH receptors was 28 +/- 2 h (mean +/- SEM; n = 4). Scatchard analysis and the pattern of GnRH-stimulated LH release from densely labeled cells indicated that they bound the photoaffinity label (Kd = 0.4 nM; approximately 1 fmol receptor/microgram DNA) and secreted gonadotropin normally. Additionally, treatment with PMA caused a significant increase (181 +/- 24%) in photoaffinity agonist binding, consistent with previous observations.

SIIp: a unique secretogranin/chromogranin of the pituitary released in response to gonadotropin-releasing hormone.

A monoclonal antibody prepared by immunization of mice with a rat pituitary granule fraction stained a single band on a Western blot of pituitary homogenate (bovine, ovine, porcine, or rat) with an apparent mol wt of 78,000 (7.5% acrylamide gel in sodium dodecyl sulfate) and pI 5.0-5.1 (isoelectric focusing). Subcellular fractionation studies of rat pituitaries indicated that the determinant of the monoclonal antibody was markedly enriched in the secretory granule fraction, an observation that was independently confirmed by immunohistochemistry of intact cells. Immunohistochemistry also indicated that this determinant was selectively located in gonadotropes and thyrotropes. On Western blots, this band comigrated with adrenal secretogranin-II (SII; chromogranin-C), had the same N-terminal sequence (six amino acids), and was heat stable (95 C; 10 min). The pituitary protein containing the determinant for the monoclonal antibody could be precipitated by a polyclonal antibody prepared by immunization of rabbits with the C-terminal sequence of adrenal SII (triodecapeptide). Conversely, the monoclonal antibody precipitated the protein containing the determinant for the polyclonal antibody. While both the monoclonal and polyclonal antisera recognized the pituitary molecule, only the polyclonal antibody recognized SII from the adrenal. A RIA was established and used to assess the release pattern of this molecule from pituitary cell cultures. Release was stimulated by GnRH and blocked by a GnRH antagonist. Release was Ca2+ dependent and stimulated by either phorbol myristyl acetate (a protein kinase-C activator) or NaF (a G-protein activator). GHRH and TRH were not as effective secretogogues as GnRH. The observations that a unique form of SII is present in the pituitary gonadotrope and secreted in response to a specific endocrine stimulus present the possibility that this substance has an endocrine function. Further, the tissue specificity of the determinant suggest that it may be useful for the specific diagnosis and monitoring of pituitary tumors.

Effect of gonadotropin-releasing hormone (GnRH) pulse frequency on serum and pituitary concentrations of luteinizing hormone and follicle-stimulating hormone, GnRH receptors, and messenger ribonucleic acid for gonadotropin subunits in cows.

Thirty-two nutritionally anestrous cows were used to determine the effect of the frequency of exogenous GnRH pulses on ovarian follicular growth, serum concentrations of LH and FSH, and concentrations of LH, FSH, GnRH receptors (GnRH-R), messenger RNA (mRNA) for GnRH-R, and mRNA for gonadotropin subunits in the pituitary. Cows were randomly assigned to one of four treatments: 2 micrograms GnRH infused (i.v.) continuously during 1 h, 2 micrograms GnRH infused during 5 min once every hour, 2 micrograms GnRH infused during 5 min once every fourth hour, or saline (control) for 13 days. Infusion of GnRH every hour increased LH concentrations in serum (P < 0.05), but FSH concentrations were not affected by GnRH infusion. Luteal activity (LA) was assessed by the presence of corpora lutea and/or serum progesterone greater than 1 ng/ml. Six of eight cows infused with GnRH every hour had LA by day 13, whereas only 25% of cows infused either continuously or with a pulse every fourth hour had LA by day 13. None of the control cows had LA during the experiment (P < 0.01). Concentrations of LH and FSH in the pituitary were significantly reduced when GnRH was infused hourly or continuously. Concentrations of common alpha and FSH beta mRNA were not influenced by treatment. However, continuous infusion of GnRH decreased (P < 0.05) LH beta mRNA subunit. Concentrations of GnRH-R (P < 0.1) and GnRH-R mRNA (P < 0.05) were reduced when GnRH was infused continuously. We concluded that pulsatile secretion of LH is necessary for follicular growth and LA in beef cattle, and GnRH treatment differentially regulates LH and FSH gene transcription and serum concentrations of LH and FSH in cattle.

Regulation of the synthetic rate of gonadotropin-releasing hormone receptors in rat pituitary cell cultures by inhibin.

Regulation of steady state levels of plasma membrane receptors for GnRH is the arithmetic result of processes that contribute to the appearance of receptors (synthesis, recycling, and unmasking) less those that contribute to the loss of receptors (degradation, internalization, and inactivation). We have adapted the density shift technique to evaluate specifically the rate of synthesis of GnRH receptors in rat pituitary cell cultures. Recently, it has been shown that inhibin can decrease the steady state levels of GnRH receptors in rat pituitary cell cultures and can block homologous up-regulation of GnRH receptors. In the present study we have evaluated the ability of purified inhibin to affect the synthesis rate of GnRH receptors under basal conditions and after exposure of cultured gonadotropes (from female weanling rats) to GnRH. Cells were exposed to inhibin alone (4 or 12 ng/ml) or to GnRH (10(-10) M) plus inhibin (0.4, 4, or 12 ng/ml) in the presence of densely labeled amino acids. GnRH was administered as a 20-min pulse, but inhibin treatment was continued for up to 2 days. After these treatments, GnRH receptors were covalently linked to a radio-labeled photoaffinity probe (125I- Tyr5-[azido-benzoyl-D-Lys6] GnRH) and solubilized with 1% sodium dodecyl sulfate. Newly synthesized GnRH receptors (those that had incorporated the dense amino acids) were separated from previously synthesized receptors (those containing normal amino acids) by velocity sedimentation through sucrose gradients (O-20% sucrose, 1% sodium dodecyl sulfate, and 10 mM Tris-HCl, pH 7.0; centrifuged at 156,000 x g for 24 h). After velocity sedimentation, gradients were fractionated, and the radioactivity in each fraction was quantified. Treatment with inhibin alone had no effect on the synthesis rate of GnRH receptors compared to that of control cultures (t1/2, 23.5 +/- 0.3 vs. 23.3 +/- 0.3 vs. 22.9 +/- 0.9 h for control, 4 ng/ml inhibin, and 12 ng/ml inhibin, respectively). In contrast, inhibin blocked the stimulation of homologous receptor synthesis by GnRH in a dose-dependent manner (t1/2, 12.2 +/- 0.7 vs. 14.0 +/- 0.7 vs. 19.2 +/- 1.5 vs. 20.0 +/- 2.9 h for GnRH alone and GnRH plus 0.4, 4, or 12 ng/ml inhibin, respectively). These data indicate that in rat pituitary cell cultures, inhibin does not decrease basal levels of GnRH receptors by affecting the synthesis rate of receptors, but prevents up-regulation of GnRH receptors by blocking stimulation of GnRH receptor synthesis by homologous hormone.

Exposure of neonatal male rats to estrogen induces abnormal morphology of the penis and loss of fertility.

The research objectives are to determine whether estrogen-induced infertility is associated with abnormal morphology of the penis and if morphological alterations can be reversed by testosterone (T). Male pups received diethylstilbestrol (DES) on alternate days from postnatal days 2 to 12. They received T or empty implants at 180 days, were tested for fertility at 188 days, and terminated at 200 days. While 5/7 control males sired pups, only 1/6 did in the DES group, and 0/8 in the DES plus T group. In addition to reductions in penile length and weight, the novel structural change induced by DES, and not reversed by T, was a replacement of cavernous spaces by fat cells in the penis body. Hence, T substitution for 8 days at adulthood did not reverse infertility in rats treated neonatally with DES and provided evidence that infertility probably resulted from absence of cavernous spaces and/or accumulation of fat cells in the penis body.

Expression of insulin-like growth factor binding protein (IGFBP)-3, and the effects of IGFBP-2 and -3 in the bovine corpus luteum.

The present study was conducted to gain insight into the insulin-like growth factor (IGF) system in the bovine corpus luteum (CL). Specific aims were to measure the levels of IGF binding protein-3 (IGFBP-3) and RNA encoding IGFBP-3 in the CL throughout diestrus, and to investigate the effects of IGFBP-2 and -3 on IGF-I-stimulated progesterone (P4) production and IGF-I-receptor binding. Bovine CL were collected from a local abattoir and classified according to stage of diestrus based on anatomical characteristics. Corpora lutea from early, mid and late diestrus were each analyzed for the presence of IGFBP-3 by ligand blot analysis, and for RNA encoding IGFBP-3 by Northern blot analysis. Dissociated cells from mid-cycle CL were treated with IGF-I, IGFBP-2 or -3, or a combination of IGF-I and IGFBP-2 or -3. The effect of IGFBP-2 and IGFBP-3 on [(125)I] IGF-I binding to its receptor on CL plasma membranes also was investigated. IGFBP-3 protein and RNA expression were higher in early CL, compared to mid or late CL (p < 0.05). IGF-I stimulated P4 production in a dose-dependant manner (p < 0.05). IGFBP-2 and -3 blocked the stimulatory effect of IGF-I on P4 production (p < 0.05). Both IGFBP-2 and -3 inhibited [(125)I]-IGF-I binding to its receptor in a dose-dependant manner. These results demonstrate that IGFBP-3 protein and RNA are expressed predominantly during early diestrus in the bovine CL. Moreover, both IGFBP-2 and -3 can modulate IGF-I actions in the CL by interfering with binding of IGF-I to its receptor.

Nuclear changes in ovine luteal cells in response to PGF2 alpha.

Percentages of normal and apoptotic parenchymal cells, fibroblasts and endothelial cells in ovine corpora lutea at 12, 24 and 36 hr following administration of a luteolytic dose of PGF2 alpha were determined and compared to percentages for identical cell types in corpora lutea removed from control ewes on days 10 (n = 5) and 12 (n = 6) postestrus. In corpora lutea obtained from control ewes greater than or equal to 95% of nuclei examined were scored normal for each of the respective cell types with no difference (P greater than .05) observed between luteal tissue obtained on days 10 and 12 postestrus. Following treatment with PGF2 alpha there were significant (P less than .05) reductions in the percentages of nuclei scored normal. Compared to controls the percentage of endothelial cell nuclei scored normal was reduced at 12 hr following PGF2 alpha-treatment; however significant reductions in percentages of parenchymal and fibroblast nuclei scored normal were not evident until 24 and 36 hr, respectively. Consistent with the concept of apoptosis, nuclear condensation and/or margination indicative of apoptosis did not occur synchronously within a given cell type: i.e., irrespective of the time point examined some cells appeared normal, whereas others had undergone nuclear condensation and/or margination. A sequence of events to explain structural and functional changes that occur during luteolysis following the interaction of PGF2 alpha with specific receptors in large steroidogenic luteal cells is discussed.

Influence of estradiol, progesterone, and nutrition on concentrations of gonadotropins and GnRH receptors, and abundance of mRNA for GnRH receptors and gonadotropin subunits in pituitary glands of beef cows.

Nutritionally induced anovulatory cows (n = 28) were used to determine the effect of steroids on regulation of synthesis and secretion of gonadotropins. Anovulatory cows were ovariectomized and received intravaginal inserts containing estradiol (E2), progesterone (P4), E2 and P4 (E2P4), or a sham intravaginal insert (C) for 7 d. Concentrations of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were quantified in serum and E2 and P4 were quantified in plasma. Cows were exsanguinated within 1 to 2 h after removal of intravaginal inserts and pituitary glands were collected and stored at -80 degrees C until messenger ribonucleic acid (mRNA) for gonadotropin-releasing hormone receptor (GnRH-R) and gonadotropin subunits, pituitary content of GnRH-R, and LH and FSH were quantified. Pituitary glands from five proestrous cows were harvested to compare gonadotropin characteristics between ovariectomized, anovulatory cows and intact cows. Plasma concentrations of E2 were greater (P < 0.05) in E2-treated cows than in sham-treated cows. Concentrations of P4 were greater (P < 0.05) in cows treated with P4 than in sham-treated cows. Mean serum concentrations of LH and FSH were not significantly influenced by steroid treatments. However, frequency of LH pulses of ovariectomized, nutritionally induced anovulatory cows was increased (P < 0.05) by treatment with E2 and amplitude of LH pulses was greater (P < 0.05) in cows treated with E2 or P4 than in cows treated with E2P4 or sham-treated. Quantity of mRNA for LHbeta in the pituitary gland was greater when cows were treated with P4. Concentrations of LH in the pituitary gland were not affected by steroid treatments; however, pituitary concentrations of FSH were less (P < 0.1) in E2 cows than in sham-treated cows. The number of GnRH-R was increased (P < 0.05) in cows treated with E2, but P4 treatment did not influence the number of GnRH-R. Abundance of mRNA for GnRH-R, common alpha-subunit, and FSHbeta were not affected by treatments. Pituitary concentrations of LH were greater (P < 0.05) and concentrations of FSH were less (P < 0.05) in proestrous cows than in ovariectomized, anovulatory cows treated with or without steroids. Abundance of mRNA for GnRH-R, common alpha-subunit, LHbeta and FSHbeta were similar for proestrous and anovulatory cows. We conclude that treatment of nutritionally induced anovulatory cows with progesterone and estradiol may cause pulsatile secretion of LH.

Comparison of full- and partial-thickness autogenous skin transplantation in dogs: a pilot study.

Thin partial-thickness (0.063 cm), medium (0.127 cm) partial-thickness, and full-thickness skin autografts were transplanted to surgically created granulating foreleg wounds of dogs. Thin partial-thickness grafts had an 89% survival, medium partial-thickness grafts had 47% survival, and full-thickness grafts had a 58% survival. Of the successful grafts, only the thin partial-thickness grafts did not grow adequate hair after transplantation.

Effects of interleukins on secretion of luteinizing hormone from ovine pituitary cells.

OBJECTIVE: To determine whether cytokines of homologous species might mediate the stimulatory effects of endotoxin on release of luteinizing hormone (LH) from pituitary cells. SAMPLE POPULATION: Cells from pituitary glands collected from 8- to 14-month-old wethers. PROCEDURE: Cells from the anterior pituitary gland were cultured in the presence of recombinant ovine or bovine cytokines (interleukin [IL]-1alpha, IL-1beta, and IL-2), tumor necrosis factor-alpha (TNF), and interferon-gamma (IFN-gamma). Luteinizing hormone that was released into the medium was measured. Cells were also cultured with modulators of signal transduction pathways to evaluate the second messenger system used by IL-1 alpha and IL-1beta. RESULTS: Similar to effects of endotoxin, IL-1alpha and IL-1beta stimulated release of LH. Interleukin 2, TNF, and IFN-gamma did not have a detectable effect on release of LH. Stimulation of LH release by IL-1alpha and IL-1beta required activation of voltage-dependent Ca2+ channels and appeared to involve protein kinase C. CONCLUSIONS: IL-1alpha and IL-1beta may mediate the direct stimulatory effect of endotoxin on release of LH in vitro. Interleukin 2, TNF, and IFN-gamma do not have a direct effect on release of LH; therefore, they do not mediate this effect of endotoxin. CLINICAL RELEVANCE: Stressors, including infection, are often associated with reduced fertility. Infection resulting in endotoxin release, production of interleukins, or both, can lead to direct stimulation of LH release from the pituitary gland. Inopportune release of LH via cytokines may interfere with normal pulsatile release of LH, thereby suppressing gonadal function.

Percutaneous biopsy of the proximal humeral growth plate in dogs.

A percutaneous biopsy technique for the study of endochondral bone formation in the dog was developed. With the dogs under general anesthesia or sedated with a combination of a tranquilizer and a local anesthetic, biopsy specimens were obtained from the proximal growth plate of the humerus with the use of a Jamshidi bone biopsy needle. Biopsy specimens were structurally intact, and contained epiphysis, growth plate, and metaphysis. The procedure proved to be a simple, safe technique, which caused minimal discomfort for the patient and did not affect the growth of the proximal end of the humerus, even after multiple biopsies.

Use of force-plate analysis of gait to compare two surgical techniques for treatment of cranial cruciate ligament rupture in dogs.

OBJECTIVE: To use ground reaction forces and related impulses as an objective measurement of limb function in the comparison of 1 extracapsular and 1 intracapsular surgical technique for repair of cranial cruciate ligament rupture in dogs. ANIMALS: 18 healthy dogs. DESIGN: All dogs underwent force-plate analysis of gait prior to transection of the left cranial cruciate ligament. The dogs were randomly allotted to 3 groups. The ligamentous instability was corrected, using a modified retinacular imbrication technique (MRIT) in 1 group and an under-and-over technique in another group. No attempt was made to correct the ligamentous instability in a control group. Clinical grading of lameness and force-plate analysis of gait were performed at 4, 8, 12, 16, and 20 weeks after surgery. PROCEDURE: Peak vertical force and vertical, braking, and propulsion impulses were recorded for each limb at each time. The degree of clinical lameness was graded at each time. RESULTS: Left hind limb peak vertical forces and vertical impulses were significantly decreased at all times after surgery in the control and under-and-over technique group, compared with values before surgery. Dogs of the MRIT group had improved by 20 weeks, with no significant differences between left hind limb peak vertical forces or vertical impulses recorded before surgery and at 20 weeks. CONCLUSION: Peak vertical forces and vertical impulses in dogs undergoing MRIT repair after experimentally created cranial cruciate ligament rupture are not significantly different when values recorded for the operated limb at 20 weeks after surgery are compared with those recorded prior to surgery.

Posologic evaluation of clindamycin, using a canine model of posttraumatic osteomyelitis.

Posttraumatic osteomyelitis attributable to Staphylococcus aureus infection was experimentally induced in 30 dogs, after which the dogs were treated with clindamycin at various dosage regimens. Of the regimens evaluated, oral administration of 11 mg of clindamycin/kg of body weight twice daily for 28 days was the most effective treatment for the osteomyelitis.